|Goran Ando (CEO)|
In 1999 the Company led consolidation in the UK biosciences market merging with Chiroscience plc and then buying Medeva plc. Then in 2000 it bought Cistron, a US biosciences business. It expanded into Germany in 2001 buying Thiemann, a German biosciences business, and went on to buy Oxford Glycosciences in July 2003 for £102m. Celltech was acquired by UCB, a Belgian drugmaker, in 2004. Since then it has been known as UCB Celltech.
The Company was engaged in research and development of therapies for patients with serious diseases. Products included:
- Tussionex for coughs
- Zaroxolyn for resistant edema
- Methylphenidate for ADHD
- Amphetamine for ADHD and narcolepsy, as 5 mg Dexedrine tablets
- Semprex-D, an antihistamine and decongestant
- Pharmatelevision[permanent dead link]
- UK Biotech Industry Consolidates As Celltech Buys Medeva for $915m[permanent dead link]
- UK's Celltech Buys Cistron of the US[permanent dead link]
- Celltech acquires German sales and marketing firm Thiemann for $44.6 mill[permanent dead link]
- ISIS Archived September 17, 2014, at the Wayback Machine.
- Belgian drugmaker seeks to buy Celltec[permanent dead link]
- Businessweek: Celltech Group Archived September 8, 2012, at the Wayback Machine.